Xeris Biopharma announces Orange Book listing of U.S. patent for Recorlev

Xeris Biopharma (XERS) announced the U.S Patent and Trademark Office has issued patent number 12,377,096 to the company for Recorlev and that this patent is now listed in the publication, “Approved Drug Products with Therapeutics Equivalence Evaluations,” commonly known as the “Orange Book.” This patent, entitled “Methods of Treating Disease with Levoketoconazole,” covers therapeutic uses of levoketoconazole in methods that minimize drug-drug interactions between levoketoconazole and other commonly co-administered drugs known as MATE1 substrates, and extends to March 2040.